Menu
Search
|

Menu

Close
X

Puma Biotechnology Inc PBYI.OQ (NASDAQ Stock Exchange Global Select Market)

23.58 USD
+0.97 (+4.29%)
As of Nov 16
chart
Previous Close 22.61
Open 22.59
Volume 395,331
3m Avg Volume 292,192
Today’s High 23.90
Today’s Low 22.42
52 Week High 108.50
52 Week Low 17.62
Shares Outstanding (mil) 37.21
Market Capitalization (mil) 4,516.76
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.89 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
180
FY17
28
FY16
0
FY15
0
EPS (USD)
FY18
-2.191
FY17
-7.858
FY16
-8.294
FY15
-7.445
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
37.46
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-224.57
15.05
Return on Equity (TTM)
vs sector
-233.95
16.62

EXECUTIVE LEADERSHIP

Alan Auerbach
Chairman of the Board, President, Chief Executive Officer, Since 2011
Salary: $732,527.00
Bonus: $404,362.00
Maximo Nougues
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Charles Eyler
Senior Vice President - Finance and Administration, Treasurer, Since 2011
Salary: $406,879.00
Bonus: $156,648.00
Douglas Hunt
Senior Vice President, Regulatory Affairs, Medical Writing and Project Management, Since 2018
Salary: --
Bonus: --
Richard Bryce
Chief Scientific Officer, Chief Medical Officer, Since 2017
Salary: $430,475.00
Bonus: $175,013.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10880 Wilshire Blvd Ste 2150
LOS ANGELES   CA   90024-4106

Phone: +1424.2486500

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

SPONSORED STORIES